ISRCTN13877948 https://doi.org/10.1186/ISRCTN13877948

Phase I trial MM-402-101

Submission date 14/05/2024	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol
Registration date 21/05/2024	**Overall study status** Deferred	[_] Statistical analysis plan [_] Results
Last Edited 13/01/2026	**Condition category** Other	[_] Individual participant data [X] Record updated in last year

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Public, Scientific, Principal investigator

Contact name
Dr David Gregory

Contact details
11 Tiger Court
Kings Drive Prescot
Liverpool
United Kingdom
L34 1BH
+44 (0)1514824700
davidgregory@macplc.com

Type(s)
Scientific

Contact name
None Jo Brady

Contact details
Senior Consultant
DLRC Regulatory Consultancy
Suite 201, The Nexus Building, Broadway
Letchworth Garden City
United Kingdom

Herts SG6 3TA
+44 01462 372472
Jo.Brady@dlrcgroup.com

Additional identifiers

Integrated Research Application System (IRAS)
1007767

Study information

Scientific Title
Phase I trial MM-402-101 [The full scientific title will be published within 30 months after the end of the trial]

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 24/10/2023, Wales Research Ethics Committee 1 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922940912; wales.rec1@wales.nhs.uk), ref: 23/WA/0135 and CTA 57953/0002/001-0001

Primary study design
Interventional

Study design
Phase I study in 40 healthy volunteers

Study type(s)
Safety, Other

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
14/10/2024

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Total final enrolment
0

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
10/05/2024

Date of final enrolment

30/09/2024

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
MAC Clinical Research Liverpool
11 Tiger Court
King's Business Park
Liverpool
England
L34 1BH

Study participating centre
MAC Clinical Research Manchester
Citylabs 1.0
Nelson St
Manchester
England
M13 9NQ

Sponsor information

Organisation
Mind Medicine Inc.

Funder(s)

Funder type
Industry

Funder Name
Mind Medicine Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available